CBO Comparison of Brand-Name Drug Prices Among Selected Federal Programs

On February 18, 2021, the Congressional Budget Office (CBO) published a report entitled, A Comparison of Brand-Name Drug Prices Among Selected Federal Programs. The federal government is a major purchaser of prescription drugs, both directly through federal agencies, such as the Department of Defense (DOD), and indirectly through federal health insurance programs, such as Medicare Part D. In this report, the CBO describes how the prices of brand-name prescription drugs are determined in different federal programs and compares drug prices among those programs in 2017.

https://www.cbo.gov/system/files/2021-02/56978-Drug-Prices.pdf